(Q47643599)

English

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

scientific article published on 30 January 2018

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial (English)

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Middle East respiratory syndrome coronavirus

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Middle East respiratory syndrome

1 reference

based on heuristic

inferred from title

lopinavir/ritonavir

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Ahmad M Deeb

9

0 references

Frederick G Hayden

27

object named as

Frederick G Hayden

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

author name string

Yaseen M Arabi

1

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Adel Alothman

2

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Hanan H Balkhy

3

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Abdulaziz Al-Dawood

4

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Sameera AlJohani

5

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Shmeylan Al Harbi

6

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Suleiman Kojan

7

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Majed Al Jeraisy

8

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Abdullah M Assiri

10

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Fahad Al-Hameed

11

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Asim AlSaedi

12

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Yasser Mandourah

13

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Ghaleb A Almekhlafi

14

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Nisreen Murad Sherbeeni

15

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Fatehi Elnour Elzein

16

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Javed Memon

17

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Yusri Taha

18

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Abdullah Almotairi

19

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Khalid A Maghrabi

20

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Ismael Qushmaq

21

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Ali Al Bshabshe

22

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Ayman Kharaba

23

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Sarah Shalhoub

24

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Jesna Jose

25

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Robert A Fowler

26

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Mohamed A Hussein

28

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

And the MIRACLE trial group

29

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

language of work or name

0 references

publication date

30 January 2018

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

19

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

1

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

81

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

copyright license

Creative Commons Attribution 4.0 International

30 January 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Middle East Respiratory Syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

A review of treatment modalities for Middle East Respiratory Syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

PubMed-cited research articles on the Middle East respiratory syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

SPIRIT 2013 statement: defining standard protocol items for clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Conducting research in disease outbreaks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Evaluating cancer patients for rehabilitation potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

22 May 2018

Non-randomised Ebola trials--lessons for optimal outbreak research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

14 August 2018

Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791210

14 August 2018

Uniform requirements for manuscripts submitted to biomedical journals

1 reference

https://pubmed.ncbi.nlm.nih.gov/29382391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13063-017-2427-0

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s13063-017-2427-0

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 February 2018

http://europepmc.org/abstract/PMC/5791210

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47643599&oldid=2236387637"